Navigation Links
VIVUS to Present at Four Upcoming Investor Conferences
Date:9/10/2010

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of September.  The conference presentation schedule is as follows:Bank of America Merrill Lynch Global Healthcare Conference Presented by: Timothy Morris, chief financial officerSeptember 16, 2010 at 2:30 p.m. BST Bank of America Merrill Lynch Financial Centre, London, UKStifel Nicolaus 2010 Healthcare ConferencePresented by: Dr. Wesley Day, vice president, clinical development September 17, 2010 at 9:45 a.m. EDTFour Seasons, Boston, MAUBS Global Life Sciences ConferencePresented by: Timothy Morris, chief financial officerSeptember 22, 2010 at 12:30 p.m. EDTThe Grand Hyatt, New York, NYThe Fifth Annual JMP Securities Healthcare ConferencePresented by: Timothy Morris, chief financial officerSeptember 28, 2010 at 8:30 a.m. EDTThe Palace Hotel, New York, NYA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com. CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923Media Relations:GolinHarrisSusan Brophysbrophy@golinharris.com312-729-4359
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
3. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
4. VIVUS to Present at Four Upcoming Healthcare Conferences
5. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. VIVUS to Present at the Needham and Company Life Sciences Conference
7. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
8. VIVUS Reports First Quarter 2009 Financial Results and Highlights
9. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Lexicon to Present at Stifel Nicolaus Healthcare Conference
11. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events and cooking ... new program offerings and company expansion. , This is largely due to ... of over 30 people. Ever since, Lajollacooks4u has seen significant demand for its services ...
(Date:12/8/2016)... December 8, 2016 AskLinkerReports.com has published ... titled Global Amyloglucosidase Industry 2016 Market Research Report. From a ... industry chain overview are all covered in the report. This ... investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
Breaking Biology Technology:
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s ... ... DERMALOG is Germany's largest Multi-Biometric ... Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is ...
Breaking Biology News(10 mins):